Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3347 - The Prognostic Role Of High Mobility Group Box Protein-1 In Glioblastoma And Its Relationship With The Inflammatory Response


10 Sep 2017


Poster display session


Translational Research;  Central Nervous System Malignancies


Mustafa Yildirim


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


M. Yildirim1, D. Süren2, A.S. Alikanoğlu3, Ö. Çakın4, İ.A. Karacay3, C. Sezer3, V. Kaya5, A. Güzel6

Author affiliations

  • 1 İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR
  • 2 Department Of Pathology, Health Science University, Antalya Education and Research Hospital, 07000 - Antalya/TR
  • 3 Department Of Pathology, Antalya Education and Research Hospital, Antalya/TR
  • 4 Department Of Anaesthesia And Reanimation, Akdeniz University School of Medicine, Antalya/TR
  • 5 Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 6 Department Of Neurosurgery, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR


Abstract 3347


In this study, the prognostic role of HMGB expression determined with immunohistochemistry in patients with glioblastoma, and the relationship with the systemic inflammatory response indicators, NLR and PLR are studied.


This study included 30 patients who had a histopathologic diagnosis of glioblastoma and 14 patients who underwent surgery for a non-tumoural intracranial pathology in Antalya Education and Research Hospital between 2008-2012. HMGB1 expression was examined via immunohistochemical method.


There were a significant difference of HMGB1 expression between the study and the control group (p = 0.002). HMGB1 expression was found positive in 23 patients (76.7%) and negative in 7 (23.3%) patients in the study group. In the control group, it was positive in 4 (28.6%) patients and negative in 10 (71.4%) patients. When NLR was used as the SIR indicator, it was determined as positive in 11 (36.7%) patients and as negative in 19 (63.3%) patients. When PLR was used as the SIR indicator, it was determined as positive in 10 (33.3%) patients and negative in 20 (66.7%) patients. Median follow up period of patients was 7.8±7.2 (Range 0.7-26.1). Median survival of the study group was 9.6±1.8 (95% Confidence Interval Range 6-13.2) (Figure 1). There wasn’t any significant difference between HMGB1 expression and survival (p = 0.692) (Figure 2). When NLR or PLR was used as the SIR indicator, there wasn’t any relation or difference determined between SIR and survival (p = 0.692, p = 0.740). A significant relation was determined between HMBG1 expression and NLR (p = 0.29). NLR was negative in 17 (73.9%) patients with positive HMGB1 expression, whereas it was negative in 2 (28.6%) patients with negative HMGB1 expression. HMGB1 expression suppresses SIR response. There wasn't any relationship between HMGB1 expression and PLR (p = 0,127).


Results we achieved in our study lead to the opinion that HMGB1 overexpression might have a role in the immune response to the developing tumour in patients with glioblastoma. While treatment strategies are developing in patients with glioblastoma, we believe that HMGB1 could be an important treatment goal.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.